SELLAS Life Sciences Announces Positive Readout for Leukemia Drug
SELLAS Life Sciences' (SLS) stock shot up as the company reported positive results from its Phase 1/2 study of its Galinpepimut-S treatment for patients with acute myeloid leukemia. The trial demonstrated that the patients treated with the drug candidate showed significant improvement in the survival rate. The median overall survival stood at 21 months while median follow-up remained at 30.8 month, in comparison to 5.4 months in patients treated with best standard care.
SELLAS had earlier reported initial data from the Phase 1/2 study